Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 16Cisplatin 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 11Paclitaxel 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Radiotherapy, Intensity-Modulated 6Cetuximab 6durvalumab 5Radiotherapy 5Radiation 5Pemetrexed 5Biopsy 5cemiplimab 4Nivolumab 4Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3Taxes 3Oxaliplatin 3ipatasertib 2fludarabine phosphate 2fludarabine 2cabozantinib 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × efineptakin alfa × 90 days × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡